Tradingfxdaily.com
  • Home
  • Forex
  • Crypto News
    • NFT News
  • World News
  • Business
  • Stock Market
  • Economic Calendar
No Result
View All Result
  • Home
  • Forex
  • Crypto News
    • NFT News
  • World News
  • Business
  • Stock Market
  • Economic Calendar
No Result
View All Result
Tradingfxdaily.com
No Result
View All Result
Home Business

J.P. Morgan Says the Stock Market Is Poised for More Upside; Here Are 2 Stocks the Banking Giant Likes

tradingfxdaily by tradingfxdaily
August 16, 2022
in Business
0
J.P. Morgan Says the Stock Market Is Poised for More Upside; Here Are 2 Stocks the Banking Giant Likes
189
SHARES
1.5k
VIEWS
Share on FacebookShare on Twitter

Related articles

Chinese Education Stocks Gain After Post-Crackdown Business Overhauls

Chinese Education Stocks Gain After Post-Crackdown Business Overhauls

January 29, 2023
This is the biggest regret most retirees have, survey shows

This is the biggest regret most retirees have, survey shows

January 29, 2023

The big question on investors’ minds right now is, where will inflation go? And the related follow-up question, for everyone, is, how far will the Fed hike rates in response? The potential answers cover the full range of possibilities, from President Biden’s happy talk about ‘zero percent inflation,’ to the market bears predicting a full-blown economic depression.

Count JPMorgan’s chief asset management strategist David Kelly among the bulls. He’s not convinced by the doomsayers, and sees the recent drop in inflation as a sign that the worst is getting behind us. While current conditions are still hard, Kelly believes that the stock market can and will show additional strength going forward. In his words, “I would be fully invested in equities at this point because I do think that equities can move higher here.”

So let’s follow JPM a little further down this trail. The banking giant’s stock analysts have picked out two stocks that they believe are ready to surge ahead – by the order of 40% or more. In fact, the JPM experts are not the only ones singing these stocks’ praises. According to the TipRanks platform – they are rated as Strong Buys by the Street’s analysts. Let’s take a closer look.

BeiGene (BGNE)

The first JPM pick is BeiGene, a clinical-stage biopharmaceutical company, with, in its words, ‘a broad and deep pipeline’ that takes a shotgun approach to the field of oncology. The company is developing a tremendous number of drug candidates, more than 50, both in-house and as collaborative efforts, to address treatment needs in some 80% of cancer malignancies. A pipeline that size gives the company a competitive advantage when compared to peers.

BeiGene is a truly international biotech firm, operating in Asia, in Europe, and in the Americas, and boasting administrative offices in Beijing, China, Cambridge, Massachusetts, and Basel, Switzerland. From these offices, the company oversees its development activities, and the commercialization activities for its line of approved commercial-stage products.

The leading approved products are zanubrutinib, branded as Brukinsa, pamiparib, branded as Partruvix, and tislelizumab, branded under its own name. As a group, these drugs are approved in several international jurisdictions for the treatment of various hematological cancers and solid tumors. BeiGene has been actively commercializing them for several years now, and in 2Q22 the company realized $304.5 million in total sales revenue. This number included $128.7 million from Brukinsa and $104.9 million in sales of tislelizumab in China. The company’s total revenue, which includes collaboration fees, reached $341.6 million, compared to $150 million in the year-ago quarter.

Covering the stock for JPMorgan, analyst Xiling Chen believes BGNE presents a compelling risk reward. Kumar rates the stock an Overweight (i.e. Buy) along with a $296 price target that implies a 50% one-year upside.

Backing his bullish stance, Chen writes: “We see BeiGene shares as undervalued given quality of assets/growth and highlight the stock as one of our top picks in the sector… BeiGene has grown into a fully integrated biopharma company with best-in-class clinical development capabilities, one of the largest and best oncology commercial platforms in China, and unmatched partnership skills with global biopharma companies. We expect the company’s 16 commercial assets and broad pipeline to drive very attractive, diversified long-term growth. While we remain moderately below consensus on long-term sales, we see additional pipeline traction as upside to our estimates…”

Overall, 6 Wall Street analysts have chimed in on this biotech giant, and left 5 Buy recommendations against 1 Hold for a Strong Buy consensus rating. The shares are priced at $192.77 and their $253.76 average price target indicates an upside potential of ~29% in the coming months. (See BGNE stock forecast on TipRanks)

Xenon Pharmaceuticals (XENE)

The second stock we’re looking at is Xenon, another biopharma firm at the clinical stage. Xenon is working on new therapeutic agents in the field of neurology, looking for novel drugs to treat neurological conditions with high unmet medical needs. The company has a particular focus on treatments for epilepsy.

Xenon has two leading drug candidates in this field, XEN496 and XEN1101, at Phase 3 and Phase 2 trials stages respectively. XEN496 is Kv7 potassium channel opener, and is being investigated for a rare pediatric form of epileptic seizure disorder. The company expects to complete the Phase 3 EPIK study of XEN496 during 2023.

XEN1101, however, is the company’s flagship drug candidate. It is currently undergoing several Phase 2 trials, for focal onset seizure epilepsy (FOS), primary generalized tonic-clonic seizures (PGTCS), and major depression. The Phase 2b X-TOLE trial, against FOS, is expected to be completed this year, and the company has two identical Phase 3 trials, X-TOLE2 and X-TOLE3, in preparation to run when the current trial is completed. The Phase 3 trials will run in parallel and enroll up to 360 patients.

Xenon is also planning the X-ACKT Phase 3 trial, to continue its study of XEN1101’s efficacy against PGTCS. This study will run simultaneously with the X-TOLE trials.

Finally, Xenon has the Phase 2 X-NOVA study ongoing to evaluate XEN1101 against major depressive disorder. Topline results from this X-NOVA study, which has enrolled 150 patients, are expected in 2023.

JPM analyst Tessa Romero sees XEN1101 as the key factor in this stock, and lays out a clear case why: “Bolstered primarily by compelling phase 2b X-TOLE data as well as positive physician feedback, we view XEN1101 as having a high probability of success as an adjunctive treatment in its lead indication of focal onset seizures (FOS). At the same time, we also see the potential for XEN1101 to work in both patients with focal and/or generalized seizures and forecast ~$1B in peak sales in the U.S. alone in the combined epilepsy indications (~$700M of which is FOS) where our estimates could prove conservative.”

“We believe there is an opportunity in XENE shares at current levels which under-reflect the potential of XEN1101 to expand to additional high unmet need indications beyond FOS where there is convincing emerging rationale,” the analyst added.

Romero rates shares in XENE as Overweight (i.e. Buy), and her $55 price target implies a 46% upside by the end of next year. (To watch Romero’s track record, click here)

Wall Street is clearly upbeat on this biopharma, as all 8 of the recent analyst reviews are positive – for a unanimous Strong Buy consensus rating. The stock is selling for $37.57 and its $51 average price target suggests ~36% one-year upside potential. (See Xenon stock forecast on TipRanks)

To find good ideas for stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights.

Disclaimer: The opinions expressed in this article are solely those of the featured analysts. The content is intended to be used for informational purposes only. It is very important to do your own analysis before making any investment.

Source link

Share76Tweet47

Related Posts

Chinese Education Stocks Gain After Post-Crackdown Business Overhauls

Chinese Education Stocks Gain After Post-Crackdown Business Overhauls

by tradingfxdaily
January 29, 2023
0

MarketsThe companies have ventured into selling fresh produce and more nonacademic tutoring Source link

This is the biggest regret most retirees have, survey shows

This is the biggest regret most retirees have, survey shows

by tradingfxdaily
January 29, 2023
0

If retirees could talk to their younger selves, they would tell them to save more for their golden years.“We think...

Ukraine willing to be neutral, says Russia wants to split nation By Reuters

North Korea calls U.S. pledge of tanks to Ukraine ‘unethical crime’ By Reuters

by tradingfxdaily
January 29, 2023
0

© Reuters. FILE PHOTO: U.S. M1A2 "Abrams" tank moves to firing positions during U.S. led joint military exercise "Noble Partner...

Louis Vuitton's Owner Is Still Reading China's Tea Leaves

Louis Vuitton's Owner Is Still Reading China's Tea Leaves

by tradingfxdaily
January 29, 2023
0

The French luxury company reported record sales in 2022 thanks to American spending, but it’s too early to say if...

Fed Set to Shrink Rate Hikes Again as Inflation Slows

Fed Set to Shrink Rate Hikes Again as Inflation Slows

by tradingfxdaily
January 28, 2023
0

(Bloomberg) -- Sign up for the New Economy Daily newsletter, follow us @economics and subscribe to our podcast.Most Read from...

Load More
  • Trending
  • Comments
  • Latest
Short SPX: Top Trade Opportunities

Short SPX: Top Trade Opportunities

April 5, 2022
The Top 5 Metaverses to Look Out for in 2022

The Top 5 Metaverses to Look Out for in 2022

March 26, 2022
What is Leverage in Forex? Forex Leverage Explained

What is Leverage in Forex? Forex Leverage Explained

April 19, 2022

Larry Fink says globalization is over — Here’s what it means for the markets

March 26, 2022
Tesla Stock Split: What to Know as EV Maker Prepares to Split Its Stock in 2022

Tesla Stock Split: What to Know as EV Maker Prepares to Split Its Stock in 2022

March 28, 2022
European equity close: Another week of gains but the momentum slows

European equity close: Another week of gains but the momentum slows

0

In a Less-Globalized World, Be Careful Where You Park Your Plane

0
Cardano pares most of its Q1 losses as ADA rebounds 60% in a month — What’s next? By Cointelegraph

Cardano pares most of its Q1 losses as ADA rebounds 60% in a month — What’s next? By Cointelegraph

0

Larry Fink says globalization is over — Here’s what it means for the markets

0
Natural-Gas Industry Gets Boost as Biden Shifts Stance

Natural-Gas Industry Gets Boost as Biden Shifts Stance

0
European equity close: Another week of gains but the momentum slows

European equity close: Another week of gains but the momentum slows

January 29, 2023
Boris Johnson: Britain will be sucked back into EU’s orbit if Labour take over

Boris Johnson: Britain will be sucked back into EU’s orbit if Labour take over

January 29, 2023
FTX Collapse: Bankman-Fried Wants to Avoid Arrest on US Soil

FTX: DOJ Seeks to Ban Bankman-Fried From Using Signal, Slack to Contact Employees

January 29, 2023
Bitcoin ‘so bullish’ at $23K as analyst reveals new BTC price metrics

Bitcoin ‘so bullish’ at $23K as analyst reveals new BTC price metrics

January 29, 2023
Chinese Education Stocks Gain After Post-Crackdown Business Overhauls

Chinese Education Stocks Gain After Post-Crackdown Business Overhauls

January 29, 2023
Tradingfxdaily.com

Tradingfxdaily.com is your Forex, Stock News, World News, Crypto Currency News, Business News & NFT News Website. We provide you with the latest breaking news and videos straight from the Trading industry.

  • Home
  • About us
  • Contact Us
  • Privacy Policy

© 2022 - All Right Reserved. tradingfxdaily.com

No Result
View All Result
  • Home
  • Forex
  • Crypto News
    • NFT News
  • World News
  • Business
  • Stock Market
  • Economic Calendar

© 2022 - All Right Reserved. tradingfxdaily.com

EURUSD=X 
$1.09  -0.16%  
EURCAD=X 
$1.45  -0.28%  
EURJPY=X 
$141.09  -0.45%  
GBPUSD=X 
$1.24  -0.10%  
EURNZD=X 
$1.67  -0.27%  
AUDUSD=X 
$0.7106  -0.15%  
CADUSD=X 
$0.7514  0.10%